ArticleBMC infectious diseases2025
Coinfection with SARS-CoV-2 among patients with Streptococcus pneumoniae in Casablanca.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pericarditis in a Child with COVID-19 Complicated byViruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the COVID-19 pandemic caused by SARS-CoV-2, coinfections with Streptococcus pneumoniae have emerged as a significant public health concern. The impact of these coinfections on disease severity and mortality rates remains underexplored. This study aims to address this gap by analyzing the clinical outcomes of patients coinfected with S. pneumoniae and SARS-CoV-2 at CHU Ibn Rochd in Casablanca, Morocco, between 2020 and 2022.
methodsA cohort of 120 hospitalized patients diagnosed with S. pneumoniae infection was studied retrospectively and prospectively. Clinical and demographic data, vaccination status, and infection characteristics were collected. Among these patients, 41 were identified as coinfected with both pathogens. Statistical analyses, including multivariate logistic regression, were performed to assess associations between coinfection and clinical outcomes, such as ICU admission and mortality.
resultsCompared to non-coinfected patients, those coinfected with SARS-CoV-2 had higher ICU admission (53.7% vs. 24.05%) and mortality (39.02% vs. 13.9%) rates. Multivariate analysis identified coinfection and increasing age as independent predictors of severe outcomes. The most frequent pneumococcal serotypes were 3, 19 A, 6 B, and 9 V, with 31.7% of cases involving non-vaccine types. Most coinfected patients, especially those who died, were unvaccinated against pneumococcus or SARS-CoV-2.
conclusionsCoinfection with SARS-CoV-2 significantly increases the risk of severe outcomes in patients with S. pneumoniae infection. These findings highlight the importance of early detection and support the implementation of comprehensive vaccination strategies targeting high-risk populations. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.